Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent
Section snippets
Acknowledgements
We thank K. Krohn, S. Lichy, and H. Wohlert for expert technical assistance and N. Holtkamp for helpful discussions. This work was funded in part by grant 325-4471-02/45 from the Federal Ministry for Health and Social Security, and by grant 01KO0111 from the Federal Ministry for Education and Research, Germany.
References (13)
- et al.
Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells
J. Biol. Chem.
(2003) - et al.
Immunomodulation of the human prion peptide 106–126 aggregation
Biochem. Biophys. Res. Commun.
(2001) - et al.
Immunization delays the onset of prion disease in mice
Am. J. Pathol.
(2002) - et al.
Anti-prion antibodies for prophylaxis following prion exposure in mice
Neurosci. Lett.
(2003) - et al.
Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody
Proc. Natl. Acad. Sci. USA
(2001) - et al.
Antiaggregating antibody raised against human PrP 106–126 recognizes pathological and normal isoforms of the whole prion protein
Cell. Mol. Neurobiol.
(2001)
Cited by (84)
Treatment of microglia with Anti-PrP monoclonal antibodies induces neuronal apoptosis in vitro
2021, HeliyonCitation Excerpt :Otherwise, many of these drugs suppress prion replication in vitro but fail to show significant efficacy in vivo. Alternative treatment strategies for prions include antibody-mediated therapy which appears to be one of the most promising approaches (Bardelli et al., 2018; Heppner et al., 2001; Schwarz et al., 2003; Sigurdsson et al., 2002; White et al., 2003). One of the earliest reports that established the proof-of-concept for in vivo prion immunotherapy demonstrated that antibodies for both PrP conformers were able to prevent prion disease onset (White et al., 2003).
Recombinant prion protein vaccination of transgenic elk PrP mice and reindeer overcomes self-tolerance and protects mice against chronic wasting disease
2018, Journal of Biological ChemistryCitation Excerpt :There are no preventive or therapeutic measures available against CWD, nor for other prion diseases such as Creutzfeldt-Jakob disease in humans, scrapie in sheep, and bovine spongiform encephalopathy in cattle. The concept of active and passive immunization has already been introduced for prion disease, and reduced prion propagation in vitro and in vivo, and it prolonged the incubation period in murine-adapted scrapie prion models after immunization (21–26). Vaccination in prion disease would be useful to prevent peripheral infection before prions reach the brain, as the vast majority of antibodies cannot cross the blood–brain barrier (25–27).
Development of a Multivalent, PrP<sup>Sc</sup>-Specific Prion Vaccine through Rational Optimization of Three Disease-Specific Epitopes
2014, VaccineCitation Excerpt :These results support the conclusion that PrPSc DSE-specific antibodies are unable to induce misfolding of PrPC in vivo or in vitro. A number of groups have provided proof-of-principle evidence suggesting immunotherapy may be of value for prion diseases [8,13,31–33]. While encouraging, these investigations typically induce immune responses that do not discriminate the healthy and infectious conformations of the prion protein.
Immunization with either prion protein fragment 95-123 or the fragment-specific antibodies rescue memory loss and neurodegenerative phenotype of neurons in olfactory bulbectomized mice
2014, Neurobiology of Learning and MemoryCitation Excerpt :Immune response against neither control (KLH-VP1 peptide and KLH) nor KLH-conjugated PrPC a.a. 200–213 fragment (PrP-II) peptides did not result in statistically significant effects on memory impairment and neurodegenerative phenotype of neurons of OBX mice indicating the specificity and PrPC domain (region) dependence of the PrP-I immunization impact. Immunogenicity and functional significance of this region was also demonstrated previously as the antibodies against either epitope 95–103 or epitope 95–123 of PrPC were able to reduce PrPSc levels in cell culture (Oboznaya et al., 2007; Peretz et al., 2001) and to inhibit prion infectivity in mice upon passive or active immunizations with respective peptide in vivo (Schwarz et al., 2003; White et al., 2003). The published data (Banks, Robinson, Diaz-Espinoza, Urayama, & Soto, 2009) that CNS injury is dependent on the presence of PrPC in both the blood and in the CNS with PrPC crossing the BBB bi-directionally (in both the brain-to-blood (efflux) and blood-to-brain (influx) directions) raised the possibility for alternative explanation of our observed PrP-I immunization impact.
Human prion disease: molecular pathogenesis, and possible therapeutic targets and strategies
2023, Expert Opinion on Therapeutic TargetsImmunization with Genetically Modified Trypanosomes Provides Protection against Transmissible Spongiform Encephalopathies
2022, International Journal of Molecular Sciences